Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LTX-315 + Pegylated liposomal-doxorubicin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LTX-315||Ruxotemitide||Ruxotemitide (LTX-315) is a 9-mer oncolytic peptide that induces release of danger-associated molecular pattern molecules (DAMPs), and may increase anti-tumor immune response and decrease tumor growth (PMID: 26982623, PMID: 30670061, PMID: 32258289).|
|Pegylated liposomal-doxorubicin||Doxil||ATI-0918|CAELYX||Chemotherapy - Anthracycline 11||Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||LTX-315 + Pegylated liposomal-doxorubicin||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with the combination of LTX-315 and Doxil (pegylated liposomal doxorubicin) resulted in increased tumor growth inhibition and regression, increased tumor necrosis, and increased T-cell infiltration in triple-negative breast cancer (TNBC) cell line xenograft models compared to either agent alone, and in TNBC models in the neoadjuvant setting induced tumor regression in 50% and improved survival compared to either agent alone (PMID: 30670061).||30670061|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|